Do analysts rate TPST or CLGN?

CollPlant Biotechnologies has a consensus target price of $120.00, suggesting a potential upside of 2,661.80%. Given CollPlant Biotechnologies' higher possible upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 CollPlant Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer TPST or CLGN?

In the previous week, Tempest Therapeutics had 3 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 5 mentions for Tempest Therapeutics and 2 mentions for CollPlant Biotechnologies. Tempest Therapeutics' average media sentiment score of 0.36 beat CollPlant Biotechnologies' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MRKR or CLGN?

In the previous week, CollPlant Biotechnologies had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for CollPlant Biotechnologies and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.00 equaled CollPlant Biotechnologies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, NCEL or CLGN?

NLS Pharmaceutics has higher earnings, but lower revenue than CollPlant Biotechnologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A CollPlant Biotechnologies $2.37M 2.64 -$11.49M -$14.50 N/A

Does the media prefer CLGN or JSPR?

In the previous week, Jasper Therapeutics had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 3 mentions for Jasper Therapeutics and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.00 beat Jasper Therapeutics' score of -0.21 indicating that CollPlant Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CLGN or CMMB?

CollPlant Biotechnologies presently has a consensus price target of $120.00, suggesting a potential upside of 2,661.80%. Given CollPlant Biotechnologies' higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Chemomab Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CollPlant Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

CollPlant Biotechnologies (CLGN) Competitors

$4.34 -0.22 (-4.71%)

As of 02:34 PM Eastern

Compare

CLGN vs. TPST, MRKR, NCEL, JSPR, and CMMB

Should you buy CollPlant Biotechnologies stock or one of its competitors? CollPlant Biotechnologies's main competitors and comparable companies include Tempest Therapeutics (TPST), Marker Therapeutics (MRKR), NLS Pharmaceutics (NCEL), Jasper Therapeutics (JSPR), and Chemomab Therapeutics (CMMB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CollPlant Biotechnologies compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

CollPlant Biotechnologies has a consensus target price of $120.00, suggesting a potential upside of 2,661.80%. Given CollPlant Biotechnologies' higher possible upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 36.2% of Tempest Therapeutics shares are held by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CollPlant Biotechnologies has higher revenue and earnings than Tempest Therapeutics. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
CollPlant Biotechnologies	$2.37M	2.64	-$11.49M	-$14.50	N/A

Tempest Therapeutics has a beta of -1.68, suggesting that its stock price is 268% less volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

In the previous week, Tempest Therapeutics had 3 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 5 mentions for Tempest Therapeutics and 2 mentions for CollPlant Biotechnologies. Tempest Therapeutics' average media sentiment score of 0.36 beat CollPlant Biotechnologies' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tempest Therapeutics has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. CollPlant Biotechnologies' return on equity of -218.81% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

Summary

Tempest Therapeutics beats CollPlant Biotechnologies on 8 of the 13 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

In the previous week, CollPlant Biotechnologies had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for CollPlant Biotechnologies and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.00 equaled CollPlant Biotechnologies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Marker Therapeutics has a net margin of -343.03% compared to CollPlant Biotechnologies' net margin of -683.68%. Marker Therapeutics' return on equity of -56.96% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-56.96%	-47.82%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

Marker Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 736.12%. CollPlant Biotechnologies has a consensus target price of $120.00, indicating a potential upside of 2,661.80%. Given CollPlant Biotechnologies' higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

CollPlant Biotechnologies has lower revenue, but higher earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	5.62	-$12.16M	-$0.41	N/A
CollPlant Biotechnologies	$2.37M	2.64	-$11.49M	-$14.50	N/A

Marker Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Marker Therapeutics beats CollPlant Biotechnologies on 9 of the 15 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

NLS Pharmaceutics has higher earnings, but lower revenue than CollPlant Biotechnologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
CollPlant Biotechnologies	$2.37M	2.64	-$11.49M	-$14.50	N/A

21.7% of CollPlant Biotechnologies shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NLS Pharmaceutics currently has a consensus price target of $23.00, suggesting a potential upside of 634.82%. CollPlant Biotechnologies has a consensus price target of $120.00, suggesting a potential upside of 2,661.80%. Given CollPlant Biotechnologies' higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, CollPlant Biotechnologies had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 2 mentions for CollPlant Biotechnologies and 1 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.00 equaled CollPlant Biotechnologies'average media sentiment score.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
CollPlant Biotechnologies	Neutral

NLS Pharmaceutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

NLS Pharmaceutics has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. NLS Pharmaceutics' return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

Summary

NLS Pharmaceutics beats CollPlant Biotechnologies on 7 of the 12 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Jasper Therapeutics?

CollPlant Biotechnologies (NASDAQ:CLGN) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, Jasper Therapeutics had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 3 mentions for Jasper Therapeutics and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.00 beat Jasper Therapeutics' score of -0.21 indicating that CollPlant Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

CollPlant Biotechnologies has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.64	-$11.49M	-$14.50	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

Jasper Therapeutics has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. CollPlant Biotechnologies' return on equity of -218.81% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Jasper Therapeutics	N/A	-884.17%	-143.83%

CollPlant Biotechnologies has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.04, meaning that its share price is 204% more volatile than the broader market.

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 3.9% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CollPlant Biotechnologies currently has a consensus target price of $120.00, suggesting a potential upside of 2,661.80%. Jasper Therapeutics has a consensus target price of $8.17, suggesting a potential upside of 1,208.76%. Given CollPlant Biotechnologies' higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Jasper Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

CollPlant Biotechnologies beats Jasper Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Chemomab Therapeutics?

CollPlant Biotechnologies (NASDAQ:CLGN) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, CollPlant Biotechnologies had 2 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for CollPlant Biotechnologies and 0 mentions for Chemomab Therapeutics. CollPlant Biotechnologies' average media sentiment score of 0.00 equaled Chemomab Therapeutics'average media sentiment score.

Company	Overall Sentiment
CollPlant Biotechnologies	Neutral
Chemomab Therapeutics	Neutral

CollPlant Biotechnologies has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Chemomab Therapeutics has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Chemomab Therapeutics' return on equity of -92.14% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Chemomab Therapeutics	N/A	-92.14%	-82.05%

CollPlant Biotechnologies presently has a consensus price target of $120.00, suggesting a potential upside of 2,661.80%. Given CollPlant Biotechnologies' higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Chemomab Therapeutics has lower revenue, but higher earnings than CollPlant Biotechnologies. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.64	-$11.49M	-$14.50	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 46.0% of Chemomab Therapeutics shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Chemomab Therapeutics beats CollPlant Biotechnologies on 7 of the 12 factors compared between the two stocks.

Get CollPlant Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLGN vs. The Competition

Export

Metric	CollPlant Biotechnologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.23M	$3.92B	$7.26B	$13.22B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-0.30	14.12	275.23	25.76
Price / Sales	2.64	1,581.23	693.23	103.04
Price / Cash	N/A	41.62	28.04	34.72
Price / Book	0.91	15.64	10.57	6.36
Net Income	-$11.49M	-$22.86M	$3.49B	$358.31M
7 Day Performance	24.50%	-1.31%	-0.20%	0.55%
1 Month Performance	39.04%	-4.56%	-2.67%	-2.88%
1 Year Performance	-82.76%	38.22%	18.26%	6.00%

CollPlant Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLGN CollPlant Biotechnologies	1.526 of 5 stars	$4.35 -4.7%	$120.00 +2,661.8%	-81.9%	$6.23M	$2.37M	N/A	39
TPST Tempest Therapeutics	1.2899 of 5 stars	$1.16 +52.9%	N/A	-90.4%	$19.35M	N/A	N/A	20	Gap Down High Trading Volume
MRKR Marker Therapeutics	2.2261 of 5 stars	$1.16 -0.9%	$10.00 +762.1%	+24.2%	$19.34M	$3.55M	N/A	60	Analyst Upgrade
NCEL NLS Pharmaceutics	1.9768 of 5 stars	$3.32 flat	$23.00 +592.8%	-84.6%	$19.19M	N/A	N/A	6	Earnings Report Analyst Upgrade Gap Up
JSPR Jasper Therapeutics	1.9746 of 5 stars	$0.57 +0.2%	$8.17 +1,330.2%	-75.3%	$19.00M	N/A	N/A	20	News Coverage Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLGN) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. TPST, MRKR, NCEL, JSPR, and CMMB

How does CollPlant Biotechnologies compare to Tempest Therapeutics?

Summary

How does CollPlant Biotechnologies compare to Marker Therapeutics?

Summary

How does CollPlant Biotechnologies compare to NLS Pharmaceutics?

Summary

How does CollPlant Biotechnologies compare to Jasper Therapeutics?

Summary

How does CollPlant Biotechnologies compare to Chemomab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. TPST, MRKR, NCEL, JSPR, and CMMB

How does CollPlant Biotechnologies compare to Tempest Therapeutics?

Do analysts rate TPST or CLGN?

Do institutionals and insiders hold more shares of TPST or CLGN?

Which has stronger valuation and earnings, TPST or CLGN?

Which has more volatility & risk, TPST or CLGN?

Does the media prefer TPST or CLGN?

Is TPST or CLGN more profitable?

Summary

How does CollPlant Biotechnologies compare to Marker Therapeutics?

Does the media favor MRKR or CLGN?

Is MRKR or CLGN more profitable?

Do analysts rate MRKR or CLGN?

Which has stronger earnings and valuation, MRKR or CLGN?

Which has more risk & volatility, MRKR or CLGN?

Do insiders & institutionals believe in MRKR or CLGN?

Summary

How does CollPlant Biotechnologies compare to NLS Pharmaceutics?

Which has better earnings & valuation, NCEL or CLGN?

Do insiders and institutionals have more ownership in NCEL or CLGN?

Do analysts prefer NCEL or CLGN?

Does the media favor NCEL or CLGN?

Which has more risk & volatility, NCEL or CLGN?

Is NCEL or CLGN more profitable?

Summary

How does CollPlant Biotechnologies compare to Jasper Therapeutics?

Does the media prefer CLGN or JSPR?

Which has stronger earnings and valuation, CLGN or JSPR?

Is CLGN or JSPR more profitable?

Which has more volatility & risk, CLGN or JSPR?

Do insiders & institutionals hold more shares of CLGN or JSPR?

Do analysts prefer CLGN or JSPR?

Summary

How does CollPlant Biotechnologies compare to Chemomab Therapeutics?

Does the media prefer CLGN or CMMB?

Which has more risk and volatility, CLGN or CMMB?

Is CLGN or CMMB more profitable?

Do analysts prefer CLGN or CMMB?

Which has better valuation and earnings, CLGN or CMMB?

Do institutionals and insiders hold more shares of CLGN or CMMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools